The first guidelines for the screening, monitoring and treatment of interstitial lung disease (ILD) in patients with systemic autoimmune rheumatic diseases (SARDs) are now available after a major multidisciplinary effort by the ACR and the American College of Chest Physicians. These guidelines demonstrate that multidisciplinary collaborations can improve SARD-ILD management.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Travis, W. D. et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med. 188, 733–748 (2013).
Luppi, F. et al. Lung complications of Sjogren syndrome. Eur. Respir. Rev. 29, 200021 (2020).
Johnson, S. R. et al. 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) guideline for the screening and monitoring of interstitial lung disease in people with systemic autoimmune rheumatic diseases. Arthritis Rheumatol. 76, 1201–1213 (2024).
Johnson, S. R. et al. 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases. Arthritis Rheumatol. 76, 1182–1200 (2024).
Flaherty, K. R. et al. Nintedanib in progressive fibrosing interstitial lung diseases. N. Engl. J. Med. 381, 1718–1727 (2019).
Levi, Y. et al. Rheumatological assessment is important for interstitial lung disease diagnosis. J. Rheumatol. 45, 1509–1514 (2018).
Fischer, A. & Du Bois, R. M. Interstitial lung disease in connective tissue disorders. Lancet 380, 689–698 (2012).
Du Bois, R. M. et al. 6-minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. Eur. Respir. J. 43, 1421–1429 (2014).
Matteson, E. L. et al. Nintedanib in patients with autoimmune disease-related progressive fibrosing interstitial lung diseases: subgroup analysis of the INBUILD trial. Arthritis Rheumatol. 74, 1039–1047 (2022).
Solomon, J. J. et al. Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Respir. Med. 11, 87–96 (2023).
Acknowledgements
The work of F.L. is partially supported by a grant from the Italian MUR Dipartimenti di Eccellenza 2023–2027 (l. 232/2016, art. 1, commi 314–337).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Luppi, F., Sebastiani, M. Guiding ILD management in systemic autoimmune rheumatic diseases. Nat Rev Rheumatol (2024). https://doi.org/10.1038/s41584-024-01160-2
Published:
DOI: https://doi.org/10.1038/s41584-024-01160-2
